Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns

Cytokine

Volumn 69, Issue 1, 2014, Pages 22-28

  Wells Logan, J ^a   Allred, Elizabeth N ^b,c,d   Fichorova, Raina N ^b,e,f   Engelke, Stephen ^g   Dammann, Olaf ^h,i   Leviton, Alan ^b,c   Lee, Kathleen ^c   McGovern, Anne ^c   Gambardella, Jill ^c   Ursprung, Susan ^c   Blomquist, Ruth ^c   Shah, Bhavesh ^j   Christianson, Karen ^j   Martin, Camilia R ^k   Van Marter, Linda J ^f   Insoft, Robert M ^l   Wilson, Jennifer G ^l   Pimental, Maureen ^l   Cole, Cynthia ^m   Fiascone, John M ^m   Madden, Janet ^m   Nylen, Ellen ^m   Furey, Anne ^m   Bednarek, Francis ⁿ   Naples, Mary ⁿ   Powers, Beth ⁿ   Ehrenkranz, Richard ^o   Williams, Joanne ^o   Romano, Elaine ^o   O'Shea, T Michael ^p   Gordon, Debbie ^p   Harold, Teresa ^p   Engelke, Stephen C ^q   Moseley, Sherry ^q   Pare, Donna ^q   Bose, Carl ^r   Bose, Gennie ^r   Poortenga, Mariel ^s   Sutton, Dinah ^s   Solomon, Carolyn ^t   Paneth, Nigel ^u   Karna, Padmani ^u   Lenski, Madeleine ^u   Schreiber, Michael D ^v   Yoon, Grace ^v   Batton, Daniel ^w   Kring, Beth ^w   Wood, Ken ^x   Hirtz, Deborah ^y   more..

^a OHIO STATE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Department of Obstetrics Gynecology and Reproductive Biology ^*  (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g EAST CAROLINA UNIVERSITY   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j BAYSTATE MEDICAL CENTER   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m TUFTS MEDICAL CENTER   (United States)

ⁿ University of Massachusetts   (United States)

^o YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p WAKE FOREST UNIVERSITY   (United States)

^q University Health Systems of Eastern Carolina   (United States)

^r North Carolina Children's Hospital   (United States)

^s HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^t Claire Dart Stroke Center Sparrow Hospital   (United States)

^u MICHIGAN STATE UNIVERSITY   (United States)

^v UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^w WILLIAM BEAUMONT HOSPITAL   (United States)

^x FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^y NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

more..

Author keywords

Acute phase; Cytokine; Infant; Premature; Protein

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CXCL11 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; MYELOPEROXIDASE; RANTES; SOMATOMEDIN BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CELL ADHESION MOLECULE; CYTOKINE; MATRIX METALLOPROTEINASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; EXTREMELY PREMATURE NEWBORN; GESTATIONAL AGE; HUMAN; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; POSTNATAL CARE; PREMATURITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; BLOOD; DRIED BLOOD SPOT TESTING; METABOLISM; NEWBORN;

CELL ADHESION MOLECULES; CYTOKINES; DRIED BLOOD SPOT TESTING; ERYTHROPOIETIN; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFLAMMATION; MATRIX METALLOPROTEINASES;

EID: 84901593946     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.04.009     Document Type: Article

References (48)

1. Juul S.E., Anderson D.K., Li Y., Christensen R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43(1):40-49.
2. Yu X., Shacka J.J., Eells J.B., Suarez-Quian C., Przygodzki R.M., Beleslin-Cokic B., et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002, 129(2):505-516.
3. Chen Z.Y., Asavaritikrai P., Prchal J.T., Noguchi C.T. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007, 282(35):25875-25883.
4. Foley R.N. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 2008, 13(4):405-414.
5. Nairz M., Schroll A., Moschen A.R., Sonnweber T., Theurl M., Theurl I., et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 2011, 34(1):61-74.
6. Gorio A., Gokmen N., Erbayraktar S., Yilmaz O., Madaschi L., Cichetti C., et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 2002, 99(14):9450-9455.
7. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001, 98(7):4044-4049.
8. Ozturk E., Demirbilek S., Kadir But A., Saricicek V., Gulec M., Akyol O., et al. Antioxidant properties of propofol and erythropoietin after closed head injury in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(6):922-927.
9. Kawakami M., Sekiguchi M., Sato K., Kozaki S., Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001, 276(42):39469-39475.
10. Campana W.M., Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 2001, 15(10):1804-1806.
11. Wang L., Zhang Z., Wang Y., Zhang R., Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35(7):1732-1737.
12. Rees S., Hale N., De Matteo R., Cardamone L., Tolcos M., Loeliger M., et al. Erythropoietin is neuroprotective in a preterm ovine model of endotoxin-induced brain injury. J Neuropathol Exp Neurol 2010, 69(3):306-319.
13. Rees S., Harding R., Walker D. The biological basis of injury and neuroprotection in the fetal and neonatal brain. Int J Dev Neurosci 2011, 29(6):551-563.
14. Ohls R.K., Harcum J., Schibler K.R., Christensen R.D. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997, 131(5):661-665.
15. Aher S.M., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012, 9:CD004868.
16. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012, 10:CD004865.
17. Hellstrom A., Smith L.E., Dammann O. Retinopathy of prematurity. Lancet 2013.
18. Elliot J.M., Virankabutra T., Jones S., Tanudsintum S., Lipkin G., Todd S., et al. Erythropoietin mimics the acute phase response in critical illness. Crit Care 2003, 7(3):R35-R40.
19. Ferrucci L., Guralnik J.M., Woodman R.C., Bandinelli S., Lauretani F., Corsi A.M., et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005, 118(11):1288.
20. Ramadori P., Ahmad G., Ramadori G. Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. Lab Invest 2010, 90(9):1306-1324.
21. O'Shea T.M., Allred E.N., Dammann O., Hirtz D., Kuban K.C., Paneth N., et al. The ELGAN study of the brain and related disorders in extremely low gestational age newborns. Early Hum Dev 2009, 85(11):719-725.
22. Yudkin P.L., Aboualfa M., Eyre J.A., Redman C.W., Wilkinson A.R. New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 1987, 15(1):45-52.
23. Leviton A., Paneth N., Reuss M.L., Susser M., Allred E.N., Dammann O., et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res 1999, 46(5):566-575.
24. Hecht J.L., Fichorova R.N., Tang V.F., Allred E.N., McElrath T.F., Leviton A. Relationship between neonatal blood protein concentrations and placenta histologic characteristics in extremely low GA newborns. Pediatr Res 2011, 69(1):68-73.
25. Fichorova R.N., Trifonova R.T., Gilbert R.O., Costello C.E., Hayes G.R., Lucas J.J., et al. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun 2006, 74(10):5773-5779.
26. Fichorova R.N., Richardson-Harman N., Alfano M., Belec L., Carbonneil C., Chen S., et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008, 80(12):4741-4751.
27. Leviton A., Fichorova R., Yamamoto Y., Allred E.N., Dammann O., Hecht J., et al. Inflammation-related proteins in the blood of extremely low gestational age newborns. The contribution of inflammation to the appearance of developmental regulation. Cytokine 2011, 53(1):66-73.
28. Fichorova R.N., Yamamoto H.S., Delaney M.L., Onderdonk A.B., Doncel G.F. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio 2011, 2(6):e00168-11.
29. McElrath T.F., Fichorova R.N., Allred E.N., Hecht J.L., Ismail M.A., Yuan H., et al. Blood protein profiles of infants born before 28 weeks differ by pregnancy complication. Am J Obstet Gynecol 2011, 204(5). 418 e1-418 e12.
30. Fichorova R.N., Onderdonk A.B., Yamamoto H., Delaney M.L., DuBois A.M., Allred E., et al. Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. MBio 2011, 2(1):e00280-10.
31. Brines M., Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264(5):405-432.
32. Eren Z., Coban J., Ekinci I.D., Kaspar C., Kantarci G. Evaluation of the effects of a high dose of erythropoietin-beta on early endotoxemia using a rat model. Adv Clin Exp Med 2012, 21(3):321-329.
33. Ben-Ari Z., Zilbermints V., Pappo O., Avlas O., Sharon E., Greif F., et al. Erythropoietin increases survival and attenuates fulminant hepatic failure injury induced by D-galactosamine/lipopolysaccharide in mice. Transplantation 2011, 92(1):18-24.
34. Hochhauser E., Pappo O., Ribakovsky E., Ravid A., Kurtzwald E., Cheporko Y., et al. Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfusion in an isolated mouse liver model. Apoptosis 2008, 13(1):77-86.
35. Schmeding M., Rademacher S., Boas-Knoop S., Roecken C., Lendeckel U., Neuhaus P., et al. RHuEPo reduces ischemia-reperfusion injury and improves survival after transplantation of fatty livers in rats. Transplantation 2010, 89(2):161-168.
36. Eipel C., Hubschmann U., Abshagen K., Wagner K.F., Menger M.D., Vollmar B. Erythropoietin as additive of HTK preservation solution in cold ischemia/reperfusion injury of steatotic livers. J Surg Res 2012, 173(1):171-179.
37. de Seigneux S., Ponte B., Weiss L., Pugin J., Romand J.A., Martin P.Y., et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012, 13:132.
38. Meng R., Zhu D., Bi Y., Yang D., Wang Y. Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice. PLoS One 2013, 8(1):e53557.
39. Eckardt K.U. The ontogeny of the biological role and production of erythropoietin. J Perinat Med 1995, 23(1-2):19-29.
40. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6):448-454.
41. Ballou S.P., Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992, 4(5):361-368.
42. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82(2):513-520.
43. Chen J., Connor K.M., Aderman C.M., Smith L.E. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118(2):526-533.
44. Kilpatrick L., McCawley L., Nachiappan V., Greer W., Majumdar S., Korchak H.M., et al. Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes. J Immunol 1992, 149(9):3059-3065.
45. Rathod D.B., Salahudeen A.K. Nonerythropoietic properties of erythropoietin: implication for tissue protection. J Invest Med 2011, 59(7):1083-1085.
46. Konishi Y., Chui D.H., Hirose H., Kunishita T., Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 1993, 609(1-2):29-35.
47. Cervellini I., Sacre S., Ghezzi P., Mengozzi M. Erythropoietin does not affect TNF and IL-6 production directly. J Biol Regul Homeost Agents 2013, 27(1):189-196.
48. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002, 99(16):10659-10664.